<DOC>
	<DOCNO>NCT03009227</DOCNO>
	<brief_summary>The purpose study determine wether D3 lymph node dissection give superior oncological outcome compare standard D2 lymph node dissection colon cancer</brief_summary>
	<brief_title>Study Oncological Outcomes D3 Lymph Node Dissection Colon Cancer</brief_title>
	<detailed_description>The design involve random allocation eligible patient D3 D2 lymph node dissection group 1:1 ratio . The extent colonic resection influence randomization predefined investigator prior randomization . Requirements apply center participate trial surgeon perform procedure describe protocol refer center volume surgeon 's experience evaluation non-editted video-recordings procedure . Routine quality control include requirement photograph vessel clip determine extent lymph node dissection perform thorough morphological assessment specimen . After surgery patient treat accord local standard difference wether D2 D3 lymph node dissection perform . Short-term long-term outcome register per protocol . This superiority trial evaluate statistical superiority . With 50 % five year survival accord national registry colon cancer , expect 10 % improvement survival D3 lymph node dissection , enrollment 768 patient 3 year accrual period follow 5 year follow require power 80 % . The intent-to-treat principle use data analysis .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>histologically confirm adenocarcinoma colon ( caecum , ascend , transverse , descend , sigmoid ) clinical stage T14aN02M01 ( distant metastasis must resectable ) indication surgical colonic resection ECOG status 02 At least 18 year age Written inform consent Medical psychiatric condition compromise patient 's ability give inform consent comply study protocol Pregnancy breast feed Medical contraindication surgical treatment Synchronous malignancy Nonresectable distant metastasis Colon obstruction , perforation bleed complicate tumor Indications isolate transverse colon resection Neoadjuvant chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>colon cancer</keyword>
	<keyword>lymph node dissection</keyword>
	<keyword>D3 lymph node dissection</keyword>
</DOC>